Quick Takeaways
- This page summarizes Jonathan E. Freeman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 13 Sep 2024, 14:59.
Jonathan E. Freeman - 11 Sep 2024 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Role
- Director
- Signature
- /s/ Robert M. Infarinato, Attorney-in-Fact
- Issuer symbol
- PHIO
- Transactions as of
- 11 Sep 2024
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 13 Sep 2024, 14:59:52 UTC
- Previous filing
- 22 Feb 2023
- Next filing
- 15 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Jonathan E. Freeman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 13 Sep 2024."
What Changed
- Previous filing in this sequence was filed on 22 Feb 2023.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PHIO | Common Stock, $0.0001 par value | Award | $0 | +1,000 | $0.000000 | 1,000 | 11 Sep 2024 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents shares underlying a restricted stock unit, which shares will vest on the first anniversary of the grant. |
| F2 | Includes shares of common stock underlying unvested restricted stock units. |